How USP is Tackling Split Dosages - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

How USP is Tackling Split Dosages
The US Pharmacopeia (USP) is examining the issue of uniformity of dosage units to address whether scoring yields consistent split doses. Anthony DeStefano, Ph.D., senior vice-president, general chapters and healthcare quality standards, provides an overview of the USP's work in this area.


It is our understanding that USP is examining the issue of uniformity of dosage units to address whether scoring yields consistent split doses, and how stability and friability of the splits can best be evaluated. What is the status of USP’s work on this issue? What are the key goals?

There is a draft FDA guidance that discusses tablet-scoring issues from a quality-by-design perspective, with a focus on what manufacturers need to do to demonstrate that a scored tablet can be labelled as “functionally scored”. USP is interested in developing a general chapter that would provide a test that at a minimum would define postmarket specifications, such as weight variation requirements, for demonstrating that a tablet is functionally scored.

Is USP considering harmonizing its potential new chapter on this topic with requirements proposed by the European Pharmacopoeia (Pharm.Eur.)?

USP is looking into the possibility of developing a guideline chapter that deals with large sample sizes. The USP statistics expert committee and dosage form expert committee are aware of the Pharm. Eur. general chapter and are certainly evaluating it as they consider this topic. Harmonization, to the extent possible, with general chapters from the Pharm.Eur.and other key pharmacopeias is a goal for any new general chapter under development by USP.

What current challenges is the USP aware of regarding tablet scoring for the drug development and manufacturing industry?

USP has published a stimulus article in Pharmacopeia Forum 35 (6) (2009), which received mixed comments with concerns from a wide audience including manufacturers, practitioner associations, and academic professionals. The prevalence of tablet splitting was recognized as a fact and the comments were in general supportive of USP efforts to establish standards for scored tablets and the advisability of tablet splitting. A common thread was that the ability to subdivide a tablet is implied by the score. The Pharm. Eur. standard on tablet scoring is seen as a good start with the possibility of improvement. Concerns were expressed that without evidence that the drug is uniformly distributed across a tablet, the use of weight to evaluate the quality of split tablet portions may not be adequate.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here